PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY

PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY

Bibliographic Details
Main Authors: K. Lorenz, T. Strüßmann, M. Trepel, G. Illerhaus, H. Pelz, C. Scholz, J. Duyster, R. Marks
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000851336.89795.74

Internet

http://journals.lww.com/10.1097/01.HS9.0000851336.89795.74

Similar Items